CN116139264A - Recombinant turkey herpesvirus live vector vaccine and application thereof - Google Patents
Recombinant turkey herpesvirus live vector vaccine and application thereof Download PDFInfo
- Publication number
- CN116139264A CN116139264A CN202211692459.3A CN202211692459A CN116139264A CN 116139264 A CN116139264 A CN 116139264A CN 202211692459 A CN202211692459 A CN 202211692459A CN 116139264 A CN116139264 A CN 116139264A
- Authority
- CN
- China
- Prior art keywords
- virus
- live vector
- turkey herpesvirus
- gene
- vector vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a recombinant turkey herpesvirus live vector vaccine, which comprises an H9 subtype avian influenza virus HA gene and an infectious bursal disease virus VP2 gene, and stably expresses the H9 subtype avian influenza virus HA protein and the infectious bursal disease virus VP2 protein. The invention also discloses application of the recombinant turkey herpesvirus live vector vaccine. The recombinant turkey herpesvirus live vector vaccine can induce good immune response in immune animals, has the characteristic of attenuated virus of a serum III type MDV vaccine strain, can be used as a trivalent live vector vaccine for avian influenza, infectious bursal disease and Marek's disease, and has good application prospect.
Description
Technical Field
The invention relates to the technical field of bioengineering, in particular to a recombinant turkey herpesvirus (rHVT) live vector vaccine for stably expressing an HA gene of H9 subtype avian influenza virus and an infectious bursal disease VP2 gene and application thereof.
Background
Avian influenza is an acute contagious disease that causes avian infection by avian influenza virus (avian influenza virus, AIV). Avian influenza virus belongs to the genus of A-type influenza virus of orthomyxoviridae, and can be classified into high-pathogenicity avian influenza virus and low-pathogenicity avian influenza virus according to the classification standard of OIE and the difference of virulence and pathogenicity of the virus, and H9N2 virus belongs to low-pathogenicity subtype avian influenza virus.
The H9N2 influenza virus is a low pathogenic avian influenza virus which is popular worldwide at present, and can infect birds such as chickens, ducks, quails and the like. The H9N2 subtype avian influenza virus and other pathogens are co-infected to cause the reduction of egg yield and the increase of death rate, thus causing great economic loss. At present, chicken is mainly prevented from being infected with H9N2 in an immune mode, and currently used H9N2 vaccines are inactivated vaccines, including single vaccine, multivalent inactivated vaccine and the like. However, the inactivated vaccine cannot effectively stimulate cellular immunity and mucosal immunity, so that the H9N2 infection cannot be completely prevented after the inactivated vaccine is used for immunization, and the virus is subjected to continuous variation under the immune pressure, so that the prevention and control of the H9N2 virus are not facilitated.
Infectious Bursal Disease (IBD) is caused by Infectious Bursal Disease Virus (IBDV) and damages the immune organs of chickens, causing immunosuppressive diseases. IBDV is prevalent worldwide and vaccine immunization is the primary means of controlling IBD. The vaccines commonly used at present are recombinant live vaccines, attenuated live vaccines and inactivated vaccines. At present, variant IBDV is widely popular in China and abroad, brings great economic loss to the poultry breeding industry, and is urgently needed to develop a novel vaccine for the variant IBDV.
Marek's Disease (MD) is a lymphoproliferative disease of chicken caused by Marek's Disease Virus (MDV). Since turkey Herpesviruses (HVT) have a certain evolutionary relationship with MDV viruses, and HVT is not pathogenic to chickens, HVT has been widely used to prevent MDV virulent (vMDV) infection. However, a safe and efficient live vaccine for preventing MDV virulent infection is still lacking at present.
Disclosure of Invention
The invention aims to solve the technical problem that a safe and effective vaccine capable of simultaneously preventing infection of H9 subtype avian influenza virus, infectious bursal disease virus and Marek's disease virus is lacking at present, and provides a recombinant turkey Herpesvirus (HVT) live vector vaccine which not only stably expresses H9 subtype avian influenza virus main antigen protein HA, but also stably expresses infectious bursal disease virus VP2 antigen protein, can induce good humoral immunity and cellular immune response in immune animals, and is suitable for being used as a trivalent live vector vaccine for avian influenza, infectious bursal disease and Marek's disease.
In order to solve the technical problems, the invention is realized by the following technical scheme:
in one aspect of the present invention, a recombinant turkey herpesvirus live vector vaccine is provided, which comprises an H9 subtype avian influenza virus HA gene and an infectious bursal disease virus VP2 gene, and stably expresses the H9 subtype avian influenza virus HA protein and the infectious bursal disease virus VP2 protein.
The genome of the recombinant turkey herpesvirus contains a gene for expressing the HA protein of the low-pathogenicity H9 subtype avian influenza virus, a gene for expressing the VP2 protein of the infectious bursal disease virus and a CMV eukaryotic promoter.
In a specific embodiment, the recombinant turkey herpesvirus (rvvt) stably expresses the HA gene of the H9 subtype avian influenza virus and the VP2 gene of the infectious bursal disease virus.
In one embodiment, the recombinant turkey herpesvirus (rvvt) utilizes the CMV promoter to express the HA gene of the H9 subtype avian influenza virus and the VP2 gene of the infectious bursal disease virus simultaneously with the polyA tail.
In a specific embodiment, the insertion position of the HA gene of the H9 subtype avian influenza virus in the recombinant turkey herpesvirus (rvvt) is the UL region of the turkey herpesvirus; the insertion site of the infectious bursal disease virus VP2 gene is the US region of turkey herpesvirus.
Preferably, the amino acid sequence of the H9 subtype avian influenza virus HA protein is shown as SEQ ID NO.1, and the nucleotide sequence of the H9 subtype avian influenza virus HA gene is shown as SEQ ID NO. 2.
Preferably, the amino acid sequence of the infectious bursal disease virus VP2 protein is shown as SEQ ID NO.3, and the nucleotide sequence of the infectious bursal disease virus VP2 gene is shown as SEQ ID NO. 4.
In another aspect of the invention, the use of the recombinant turkey herpesvirus live vector vaccine described above in the preparation of a vaccine for the prevention and/or treatment of avian influenza, infectious bursal disease, and Marek's disease is also provided.
The recombinant live vector vaccine of the invention is a recombinant live vector vaccine for constructing main immunoprotection antigen genes for expressing avian influenza virus and infectious bursal disease virus by using the live vector of the turkey herpesvirus, and can induce good humoral immunity and cellular immunity response in target animals, and can make up for the defect that the conventional inactivated vaccine cannot effectively activate cellular immunity. The live vector vaccine (rHVT-H9-VP 2) obtained by the invention has the characteristic of attenuated serum III type MDV vaccine strain, can be used as trivalent live vector vaccine for avian influenza, infectious bursal disease and Marek's disease, and has good application prospect.
Drawings
FIG. 1 is a diagram showing the results of PCR detection of HA and VP2 genes in rHVT-H9-VP2 of example 2 of the present invention;
FIG. 2 is an immunofluorescence of the HA protein expressed by rHVT-H9-VP2 of example 2 of the invention;
FIG. 3 is an immunofluorescence of rHVT-H9-VP 2-expressing VP2 protein of example 2 of the invention;
FIG. 4 is a graph showing the results of H9 antibody titers produced by rHVT-H9-VP 2-immunized chickens of example 3 of the invention;
FIG. 5 is a graph showing the results of the production of IBDV antibody titers by rHVT-H9-VP 2-immunized chickens of example 3 of the invention.
Detailed Description
The invention uses turkey herpesvirus as a live vector to construct a recombinant turkey herpesvirus live vector vaccine (rHVT-H9-VP 2) for expressing the HA gene of the H9 subtype avian influenza virus and the VP2 gene of the infectious bursal disease virus, and the recombinant live vector vaccine can induce good humoral immunity and cellular immunity response in a target animal body, and can make up the defect that the conventional inactivated vaccine can not effectively activate cellular immunity. The live vector vaccine provided by the invention has the characteristics of attenuated serotype III MDV vaccine strain, and can be used as trivalent live vector vaccine for avian influenza, infectious bursal disease virus and Marek's disease.
The rHVT-H9-VP2 can stably express the avian influenza virus HA protein on the cell membrane.
The HA and VP2 proteins expressed by rHVT-H9-VP2 of the invention include the HA and VP2 proteins of any avian influenza virus recognized in the art, including but not limited to the HA and VP2 proteins, and also include the main protective antigen genes of other avian pathogens.
The HA proteins of the invention also include analogs or muteins thereof, or fragments thereof. The terms "analog" and "mutein" refer to biologically active derivatives of the reference molecule, or fragments of such derivatives that retain the desired activity (e.g., immunoreactivity). In general, the term "analog" refers to a compound having the sequence and structure of a native polypeptide, as well as one or more amino acid additions, substitutions (typically conservative in nature) and/or deletions relative to the native molecule, so long as the modification does not disrupt the immunogenic activity. The term "mutein" refers to a peptide having one or more peptidomimetics ("peptoids"). Preferably, the analogue or mutein has at least the same activity or function as the natural molecule. Methods for preparing polypeptide analogs and muteins are known in the art.
Eukaryotic promoters useful in the present invention include CMV, SV40, survivin, etc., with eukaryotic promoters CMV being preferred.
In a specific embodiment, in the HVT recombinant virus, the HA gene insertion position is the UL region of the HVT virus and the VP2 gene insertion position is the US region of the HVT virus.
EXAMPLE 1 construction of rHVT-H9-VP2 recombinant Virus stably expressing HA and VP2 proteins
1. Construction of rHVT-H9 recombinant viruses
By utilizing the homologous recombination genetic manipulation technology, a homologous recombination arm (UL-homologous arm) of an HVT/FC126 virus UL region is constructed to 5 'and 3' regions of a CMV-EGFP-SV40polyA gene fragment (the nucleotide sequence of a CMV promoter is shown as SEQ ID NO.5, the nucleotide sequence of SV40polyA is shown as SEQ ID NO. 6), so that 'UL-homologous arm-CMV-EGFP-SV 40 poly-UL-homologous arm' and HVT/FC126 virus genome DNA are generated and transfected into CEF cells simultaneously, the CMV-EGFP-SV40polyA gene is inserted into the UL region of the HVT/FC126 virus genome in a homologous recombination mode, and rHVT-EGFP virus with green fluorescence is purified in a plaque purification mode. Similarly, the homologous recombination wall (UL-homology arm) of the UL region of the HVT/FC126 virus is constructed to the 5 'and 3' regions of the CMV-H9-SV40polyA gene fragment (wherein the nucleotide sequence of the H9N2 virus HA gene is shown as SEQ ID NO. 2), a "UL-homology arm-CMV-H9-SV 40 polyA-UL-homology arm" gene fragment is generated, the fragment and rHVT-EGFP genomic DNA are simultaneously transfected into CEF cells, the CMV-H9-SV40polyA fragment replaces the EGFP gene by homologous recombination, and the rHVT-H9 virus without green fluorescence is purified by plaque purification.
2. Construction of rHVT-H9-VP2 recombinant viruses
The VP2 gene of IBDV was inserted again into the US region of rHVT-H9 using the same strategy. The homologous recombination wall (US-homology arm) of the US region of the HVT/FC126 virus was constructed into the 5 'and 3' regions of the CMV-EGFP-SV40polyA gene fragment, resulting in the simultaneous transfection of the "US-homology arm-CMV-EGFP-SV 40 poly-US-homology arm" and rHVT-H9 genomic DNA into CEF cells, the CMV-EGFP-SV40polyA gene was inserted into the US region of the rHVT-H9 viral genome by homologous recombination, and the rHVT-H9-EGFP virus with green fluorescence was purified by plaque purification. Similarly, the homologous recombination arm (US-homology arm) of the US region of the HVT/FC126 virus was constructed into the 5 'and 3' regions of the CMV-VP2-SV40polyA gene fragment (wherein the nucleotide sequence of the VP2 gene of IBDV is shown in SEQ ID NO. 4), resulting in a "US-homology arm-CMV-VP 2-SV40 polyA-US-homology arm" gene fragment, which was transfected into CEF cells simultaneously with rHVT-H9-EGFP viral genomic DNA, and the CMV-VP2-SV40polyA fragment was able to replace the EGFP gene by homologous recombination, and the rHVT-H9-VP2 virus without green fluorescence was purified by plaque purification.
EXAMPLE 2 verification of rHVT-H9-VP2 recombinant virus
PCR identification
Extracting genome DNA of rHVT-H9-VP2 recombinant virus, and detecting H9 and VP2 genes in rHVT-H9-VP2 recombinant virus by PCR. As a result, rHVT-H9-VP2 was able to amplify specific bands of H9 and VP2, as shown in FIG. 1.
2. Indirect immunofluorescence assay
CEF infected with rHVT-H9-VP2 recombinant virus, and cells were washed with PBS. Cells were permeabilized and fixed in a mixture of acetone and methanol at-20℃followed by washing with PBS. Cells were incubated with PBS-M-T (5% nonfat milk powder, 0.05% Tween-20, 0.1% Triton X-100) at 37deg.C for 90min. The cells were washed 3 times with 200. Mu.L of PBST containing 0.25% Tween-20 for 3min each. H9HA polyclonal antibody diluted with PBS (PBS-M-T) containing 5% skimmed milk powder and 0.05% Tween 20 was added, and incubated at 37℃for 1H. Cleaning is the same as above. 50. Mu.L of FITC-goat anti-mouse IgG (KPL, 1:200) was diluted with PBS-M-T, incubated at 37℃for 1h, and washed as above. Finally, the results were observed with an inverted fluorescence microscope (OLYMPUS) and recorded by photographing, and the specific results are shown in fig. 2 and 3. The experimental result shows that the HA protein and VP2 protein are abundantly expressed in CEF cells, the amino acid sequence of the HA protein of the H9N2 virus is shown as SEQ ID NO.1, and the amino acid sequence of the VP2 protein of the IBDV virus is shown as SEQ ID NO. 3. In fig. 2, the left panel shows the fluorescence of H9HA protein expression, and the right panel shows control cells. In FIG. 3, the left panel shows fluorescence of VP2 protein expression, and the right panel shows control cells.
EXAMPLE 3 test of the immune Effect of recombinant turkey herpesvirus live vector vaccine (rHVT-H9-VP 2)
rHVT-H9-VP2 was infected with CEF cells, and the diseased cells were collected 3 days after infection, and virus titration was performed. To test the immune effect of rHVT-H9-VP2, 10 SPF chickens at 1 day old were immunized subcutaneously at 5000PFU dose, blood from immunized chickens was collected 28 days after immunization, serum was isolated, and Hemagglutination Inhibition (HI) and enzyme-linked immunosorbent assay (ELISA) were used. In addition, another 10 SPFs of 1 day old were subcutaneously immunized with PBS as a negative control.
Serological detection results show that rHVT-H9-VP2 induces higher H9 specific antibody 28 days after immunization, and the average HI titer reaches 2 7 (FIG. 4) PBS immunized control chickens cannot detect any antibodies in vivo, which indicates that rHVT-H9-VP2 can effectively stimulate chickens to generate specific antibodies against H9, thereby achieving an immune effect.
Similarly, ELISA serological test results show that rHVT-H9-VP2 induces higher specific antibodies against IBDV 28 days after immunization, the average ELISA (S/N) titer reaches 8 (figure 5), PBS immune control chickens cannot detect any antibodies in vivo, and the rHVT-H9-VP2 can effectively stimulate chickens to generate specific antibodies against IBDV, thereby achieving an immune effect.
The above embodiments are merely illustrative and not restrictive. The scope of the invention is to be defined by the claims. Those skilled in the art will appreciate that various modifications and changes can be made to the invention without departing from the spirit and scope of the present application, and that such modifications and changes are within the scope of the present invention.
Claims (10)
1. A recombinant turkey herpesvirus live vector vaccine, characterized in that the live vector vaccine comprises an H9 subtype avian influenza virus HA gene and an infectious bursal disease virus VP2 gene, and stably expresses the H9 subtype avian influenza virus HA protein and the infectious bursal disease virus VP2 protein.
2. The recombinant turkey herpesvirus live vector vaccine of claim 1, wherein the insertion position of the H9 subtype avian influenza virus HA gene in the live viral vector is the UL region of the turkey herpesvirus.
3. The recombinant turkey herpesvirus live vector vaccine of claim 1, wherein the infectious bursal disease virus VP2 gene is inserted in the viral live vector at a location that is the US region of the turkey herpesvirus.
4. The recombinant turkey herpesvirus live vector vaccine of claim 1, wherein the amino acid sequence of the HA protein of the H9 subtype avian influenza virus is shown in SEQ ID No. 1.
5. The recombinant turkey herpesvirus live vector vaccine according to claim 1, wherein the nucleotide sequence of the HA gene of the H9 subtype avian influenza virus is shown in SEQ ID No. 2.
6. The recombinant turkey herpesvirus live vector vaccine of claim 1, wherein the amino acid sequence of the infectious bursal disease virus VP2 protein is shown in SEQ ID No. 3.
7. The recombinant turkey herpesvirus live vector vaccine of claim 1, wherein the nucleotide sequence of the infectious bursal disease virus VP2 gene is shown in SEQ ID No. 4.
8. Use of a recombinant turkey herpesvirus live vector vaccine according to any one of claims 1-7 in the preparation of a vaccine for the prevention and/or treatment of avian influenza.
9. Use of a recombinant turkey herpesvirus live vector vaccine according to any one of claims 1-7 for the preparation of a vaccine for the prevention and/or treatment of infectious bursal disease.
10. Use of a recombinant turkey herpesvirus live vector vaccine according to any one of claims 1-7 for the preparation of a vaccine for the prevention and/or treatment of marek's disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211692459.3A CN116139264A (en) | 2022-12-28 | 2022-12-28 | Recombinant turkey herpesvirus live vector vaccine and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211692459.3A CN116139264A (en) | 2022-12-28 | 2022-12-28 | Recombinant turkey herpesvirus live vector vaccine and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116139264A true CN116139264A (en) | 2023-05-23 |
Family
ID=86359332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211692459.3A Pending CN116139264A (en) | 2022-12-28 | 2022-12-28 | Recombinant turkey herpesvirus live vector vaccine and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116139264A (en) |
-
2022
- 2022-12-28 CN CN202211692459.3A patent/CN116139264A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10655146B2 (en) | Turkey herpesvirus vectored recombinant containing avian influenza genes | |
| EP2419132B1 (en) | Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species | |
| RU2766003C2 (en) | Multivalent recombinant avian herpes viruses and vaccines for immunisation of birds | |
| JP2006348044A (en) | Avian herpesvirus-based live recombinant avian vaccine, in particular against gumboro disease | |
| US20220088187A1 (en) | Recombinant non-pathogenic marek's disease virus constructs encoding multiple heterologous antigens | |
| CN110218706B (en) | Construction and application of recombinant turkey herpesvirus expressing HA protein of H7N9 subtype highly pathogenic avian influenza virus | |
| US20070212375A1 (en) | Process For Producing In Yeast Empty Viral Capsids Consisting Of Proteins Derived From Pvp2 Of The Infectious Bursal Disease Virus (Ibdv) | |
| CN113226363A (en) | Recombinant avian herpesvirus containing multiple foreign genes | |
| JP4691495B2 (en) | Coronavirus spike S1 fusion protein and expression vector thereof | |
| JPH08508410A (en) | Recombinant avian adenovirus vector | |
| US20220062411A1 (en) | Recombinant viruses and the uses thereof | |
| Tarpey et al. | A recombinant turkey herpesvirus expressing chicken interleukin-2 increases the protection provided by in ovo vaccination with infectious bursal disease and infectious bronchitis virus | |
| WO2012117045A1 (en) | Infectious bronchitis virus (ibv) spike protein as subunit vaccine | |
| CN116139264A (en) | Recombinant turkey herpesvirus live vector vaccine and application thereof | |
| US20230372474A1 (en) | Recombinant hvt and uses thereof | |
| KR101085310B1 (en) | Infectious bursal disease virus mutants and vaccines | |
| JP3933689B2 (en) | Recombinant herpesvirus using gB gene promoter | |
| WO2000020600A1 (en) | Avian pneumovirus vaccine and diagnostic agent | |
| KR100354972B1 (en) | Recombinant Marek's disease virus type 2 expressing the S1 glycoprotein of infectious bronchitis virus and a method for constructing thereof | |
| JP3428666B2 (en) | Recombinant Marek's disease virus and its production | |
| Lai et al. | Production and purification of immunogenic virus-like particles formed by the chimeric infectious bursal disease virus structural protein, rVP2H, in insect larvae | |
| RU2812979C2 (en) | Recombinant avian herpes viruses containing several alien genes | |
| Yan et al. | Application of ORF3 Subunit Vaccine for Avian Hepatitis E Virus. Vet. Sci. 2022, 9, 676 | |
| WO2024105245A1 (en) | Recombinant marek's disease virus and uses thereof | |
| Hong-Mei et al. | Construction and immunological characterization of recombinant Marek's disease virus expressing IBDV VP2 fusion protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |